Speeches

Mark Durkan – 2016 Parliamentary Question to the Department of Health

The below Parliamentary question was asked by Mark Durkan on 2016-02-24.

To ask the Secretary of State for Health, what steps his Department is taking to ensure that approved personalised medicines are available to patients with colorectal cancer.

George Freeman

On 24 September, the NHS England Board agreed the development of a Personalised Medicine Strategy for the National Health Service. Personalised medicine is a move away from a ‘one size fits all’ approach to the treatment and care of patients with a particular condition. It uses emergent approaches in areas such as diagnostic tests, functional genomic technologies, molecular pathways, data analytics and real time monitoring of conditions to better manage patients’ health and to target therapies to achieve the best outcomes in the management of a patient’s disease or predisposition to disease. The high-level vision and strategy is to create a Personalised Medicine service in the NHS embracing four overarching principles: the prediction and prevention of disease; more precise diagnoses; targeted and personalised interventions; and a more participatory role for patients.

The independent Cancer Taskforce’s five-year strategy for cancer, Achieving World-Class Outcomes (July 2015), recommends improvements across the cancer pathway, with the aim of improving survival rates.

NHS England is currently working with partners across the health system to determine how best to take forward the recommendations of the Cancer Taskforce. NHS England has appointed Cally Palmer as National Cancer Director to lead on implementation, as well as new cancer vanguards to redesign care and patient experience. She has set up a new Cancer Transformation Board to implement the strategy, and this met for the first time on Monday 25 January. There will also be a Cancer Advisory Group, chaired by Sir Harpal Kumar, to oversee and scrutinise the work of the Transformation Board.

The Accelerated Access Review, chaired by Sir Hugh Taylor, will make recommendations to government on reforms to accelerate access for NHS patients to transformative new medicines and technologies making our country the best place in the world to design, develop and deploy these products. The terms of the reference for the review focus on faster access to innovations, which may include personalised medicines for the treatment of colorectal cancer.